Summit Therapeutics Inc. (SMMT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Summit Therapeutics Inc. ( SMMT) 44th Annual J.P. Morgan Healthcare Conference January 12, 2026 12:45 PM EST ...
More than two-thirds of deaths from ovarian cancer are attributable to high-grade serous carcinoma. In one particularly ...
Ovarian cancer often goes undetected for a long time. In seven out of 10 patients, the tumor has already formed secondary ...
NICE has proposed age-based CA125 thresholds to improve early ovarian cancer detection while reducing unnecessary scans in ...
The result is a record 18 million cancer survivors in the US right now, a number expected to grow between 300,000 and 500,000 ...
The FDA-approved drug combination specifically targets low-grade serous ovarian cancer, which primarily affects younger women ...
Scientists have discovered that key compounds from cannabis—CBD and THC—show surprisingly strong effects against ovarian cancer cells. Used together, they slow cell growth, reduce colony formation, ...
Cancer is still the most common cause of death for men in the US ages 60 to 79 and women ages 40 to 79. For all adults ...
AI has revealed why cancer survival differs so dramatically around the world, highlighting the specific health system factors that matter most in each country.
Integrating the ultrasound sliding sign helps predict stage IV ovarian endometriosis, according to a study published in Fertility and Sterility.
While rates of cancer diagnosis under age 50 have risen in recent years, this has not translated into increased cancer ...
Postoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck Cancer ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results